CLINICAL CHEMISTRY临床化学
CLINICAL CHEMISTRY(英文缩写 CLIN CHEM),ISSN 0009-9147,eISSN 1530-8561,中文译名:临床化学 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-11-01 至 2026-10-31，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 12.114 | Q1 |
| 2022 | 9.300 | Q1 |
| 2023 | 7.100 | Q1 |
| 2024 | 6.300 | Q1 |
| 2025 | 8.300 | Q1 |
CLINICAL CHEMISTRY 最新收录文献
-
2. Diagnostic Challenges in γ-Heavy Chain Disease: A Case of Overestimated IgG Concentration.
PMID:日期:2026-10-05该文献暂无摘要。
-
3. Mining and Refining Elusive Microproteins from Noncanonical Open Reading Frames.
PMID:日期:2026-10-05该文献暂无摘要。
-
4. Commentary on Diagnostic Challenges in γ-Heavy Chain Disease: A Case of Overestimated IgG Concentration.
PMID:日期:2026-10-05该文献暂无摘要。
-
5. Persistent Atypical Buprenorphine and Naloxone Metabolite Profile in Urine.
PMID:日期:2026-10-05该文献暂无摘要。
-
6. Commentary on Diagnostic Challenges in γ-Heavy Chain Disease: A Case of Overestimated IgG Concentration.
PMID:日期:2026-10-05该文献暂无摘要。
-
7. Urinary Cell-Free DNA Fragmentomics Detects Multiple Urologic Cancers and May Reduce Unnecessary Prostate Biopsies.
PMID:日期:2026-09-25Urinary cell-free DNA (ucfDNA) represents a completely noninvasive yet underutilized biospecimen for molecular diagnostics. Our group previously demonstrated that fragmentomic features of plasma cell-free DNA enable direct inference of underlying DNA methylation signals. However, the relationship between DNA methylation and fragmentomic patterns in urine, as well as their potential clinical utility, remains unexplored. We developed FRAGmentomics-based Methylation Analysis for ucfDNA (termed uFRAGMA) and evaluated its performance using 400 ucfDNA samples from patients with bladder, prostate, and kidney cancers, as well as non-cancer subjects. The ucfDNA fragmentation patterns around cancer-associated cytosine-phosphate-guanine (CpG) sites were used for cancer detection and differentiation. uFRAGMA demonstrated robust diagnostic performance across urological malignancies, achieving an area under the curve (AUC) of 0.98 for bladder cancer detection and 0.93 for kidney cancer detection. In the context of prostate cancer screening, uFRAGMA could potentially reduce unnecessary prostate biopsies by 67.5% among patients with elevated prostate-specific antigen (PSA) levels (>4 ng/mL), who would otherwise be at risk of overtreatment. Furthermore, we developed a tumor-of-origin classifier for urologic malignancies, attaining classification accuracies ranging from 71% to 92%. Our findings from this proof-of-concept study suggest that fragmentomics analysis of ucfDNA may provide a clinically meaningful, noninvasive strategy for cancer detection, localization, and risk stratification of urologic cancers, with potential to refine existing clinical practices and reduce unnecessary tissue biopsies.
-
8. Biomarker Discovery for PMM2-CDG Using Fractionated N-Glycomics Analysis.
PMID:日期:2026-09-25The most common congenital disorder of glycosylation (CDG) worldwide is phosphomannomutase 2 (PMM2)-CDG, which presents with a highly variable, multisystem clinical spectrum that poses challenges for diagnosis and prognosis. We performed N-glycomics analysis on plasma and 3 plasma fractions: affinity-purified transferrin, IgG, and a triple-depleted fraction in which IgG, transferrin, and albumin were removed. A total of 103 samples from 71 PMM2-CDG patients were analyzed. Three major glycosylation abnormalities were identified in PMM2-CDG: (a) increases in intermediate glycans derived from high-mannose glycan assembly; (b) decreases in mature/processed multi-antennary N-glycans; and (c) abnormal fucosylation and branching. Total plasma N-glycan analysis demonstrated high clinical sensitivity and specificity, with increased Man3GlcNAc2 (Man3)/Man4-6, Man3/8-9, and Man5/8 ratios detected in all patients. Novel PMM2-CDG diagnostic biomarkers were also identified from this study, including increased Man4GlcNAc2 linkage isomers in plasma and novel hybrid glycans in the transferrin fraction. When correlated with the Nijmegen Progression CDG Rating Scale (NPCRS) in a diverse cohort age >2 years (n = 39; NPCRS 10-40), 11 glycans and 10 glycan ratios from total plasma and plasma fractions showed significant associations, providing strong candidates for use as disease biomarkers for PMM2-CDG. We identified 35 plasma N-glycan biomarkers in a large cohort of patients with PMM2-CDG, identifying key glycans and glycan ratios that correlate with clinical severity. Utilizing fractionated N-glycan profiling enhanced these clinical correlations, demonstrating their strong prognostic value and promising application as surrogate biomarkers in clinical trials.
-
9. Plasma Cell Leukemia with A "Missing" Monoclonal Protein on Immunofixation.
PMID:日期:2026-09-03该文献暂无摘要。
-
10. Commentary on Plasma Cell Leukemia with a "Missing" Monoclonal Protein on Immunofixation.
PMID:日期:2026-09-03该文献暂无摘要。